Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
尼洛替尼对伊马替尼和达沙替尼治疗失败后的慢性期和加速期慢性粒细胞白血病有效。
期刊:Leukemia
影响因子:13.4
doi:10.1038/leu.2010.110
Giles, F J; Abruzzese, E; Rosti, G; Kim, D-W; Bhatia, R; Bosly, A; Goldberg, S; Kam, G L S; Jagasia, M; Mendrek, W; Fischer, T; Facon, T; Dünzinger, U; Marin, D; Mueller, M C; Shou, Y; Gallagher, N J; Larson, R A; Mahon, F-X; Baccarani, M; Cortes, J; Kantarjian, H M
